期刊文献+

司来吉兰联合左旋多巴在帕金森病运动障碍中的效果观察 被引量:8

下载PDF
导出
摘要 目的:探讨司来吉兰联合左旋多巴在帕金森病运动障碍中的应用效果。方法:随机抽取2012年3月~2017年5月本院收治的帕金森病患者92例,所有患者均合并运动障碍。按照治疗方法的不同,将92例帕金森病患者分为研究组(司来吉兰+左旋多巴,n=46)与对照组(左旋多巴,n=46)。对比两组治疗效果。结果:研究组、对照组总有效率分别为78.3%、47.8%,差异有统计学意义(P<0.05);就诊时,两组UPDRS评分对比,差异无统计学意义(P>0.05);治疗后1个月,研究组UPDRS评分明显低于对照组,差异有统计学意义(P<0.05)。结论:帕金森病运动障碍采用司来吉兰与左旋多巴联合治疗的效果理想,值得推广。
出处 《北方药学》 2018年第8期78-79,共2页 Journal of North Pharmacy
  • 相关文献

参考文献6

二级参考文献52

  • 1Bargiotas P, Konitsiotis S. Levodopa-induced dyskinesias in Parkinson's disease:emerging treatments[J]. Neuropsychiatfi Dis Treat, 2013,9 : 1605-1617. DOI : 10. 2147/NDT.S36693.
  • 2Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson' s disease [ J ]. J Neural Transm (Vienna) , 2013, 120 (9) : 1305-1320. DOI: 10. 1007/s00702- 013-0981-5.
  • 3Ahlskog JE, Muenter MD. Frenquency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [ J ]. Mov Disord,2001,16 (3) :448-458.
  • 4Iravani MM, Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharma cological manipulation [ J ]. J Neural Transm ( Vienna ), 2011, 118 ( 12 ) : 1661-1690. DOI : 10. 1007/s00702-011-0698-2.
  • 5Kipfer S, Stephan MA, Schfipbach WM, et al. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia[ J]. Arch Neurol, 2011, 68 (8) : 1037-1039. DOI: 10. 1001/archneurol. 2011. 147.
  • 6Zhang YH, Tang BS, Song CY, et al. The relationship between the phenotype of Parkinson's disease and levodopa-indueed dyskinesia [ J ] . Neurosei Lett, 2013, 556: 109-112. DOI: 10. 1016/i. neulet. 2013. 10. 018.
  • 7Jellinger IA. Recent developments in the pathology of Parkinson's disease [ J ]. J Neural Transm Suppl, 2002, (62) : 347-376.
  • 8Eggers C, Kahraman D, Fink GR, et al. Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT single photon emission computed tomography [J] . Mov Disord, 2011, 26 (3) : 416-423. DOI: 10. 1002/ mds. 23468.
  • 9Alves G, Pedersen KF, Bloem BR, et aL Cerebrospinal fluid amyloid-13 and phenotypic heterogeneity in de novo Parkinson's disease [ J ]. J Neurol neurosurgery Psychiatry, 2013, 84 (5) :537- 543. DOI: 10. 1136/jnnp-2012-303808.
  • 10Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease-The AMANDYSK triM[J]. Neurology, 2014,82(4) :300-307.

共引文献71

同被引文献42

引证文献8

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部